5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Abstract
OBJECTIVE: Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia. The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses. METHOD: Twelve patients with schizophrenia were randomly assigned to 5, 10, 15, or 20 mg/day of olanzapine in a prospective fashion. Three other subjects taking 30-40 mg/day were also included. Once steady-state plasma levels were achieved, dopamine D2 and serotonin 5-HT2 receptors were assessed by using [11C]raclopride and [18F]setoperone positron emission tomography imaging, respectively. Ratings of clinical status, extrapyramidal side effects, and prolactin levels were also obtained. RESULTS: Olanzapine induced near saturation of the 5-HT2 receptors, even at 5 mg/day. Its D2 occupancy increased with dose: patients taking 5-20 mg/day showed 43%-80% D2 occupancy, while patients taking 30-40 mg/day showed 83%-88%. CONCLUSIONS: Olanzapine is a potent 5-HT2 blocker and shows a higher 5-HT2 than D2 occupancy at all doses. However, its D2 occupancy is higher than that of clozapine and similar to that of risperidone. In the usual clinical dose range of 10-20 mg/day, its occupancy varies from 71% to 80%, and this restricted range may explain its freedom from extrapyramidal side effects and prolactin elevation. However, doses of 30 mg/day and higher are associated with more than 80% D2 occupancy and may have a higher likelihood of prolactin elevation and extrapyramidal side effects.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265 · see citing works
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179 · see citing works
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420 · see citing works
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352 · see citing works
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167 · see citing works
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061 · see citing works
Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R., Graffeo, K. A., & Thieme, M. E. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891 · see citing works
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876 · see citing works
Self-citationSerotonin-dopamine interaction and its relevance to schizophrenia
Kapur, S., & Remington, G. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 826 · see citing works
Self-citationOlanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777 · see citing works
Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors
Pazos, Á., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90326-5 · Cited by 684 · see citing works
D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 529 · see citing works
Nordström, A., Farde, L., Wiesel, F., Forslund, K., Pauli, S., Halldin, C., & Uppfeldt, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90288-o · Cited by 527 · see citing works
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T. M., SATTERLEE, W. G., Tollefson, G. D., Tran, P., & Hamilton, S. H. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390 · see citing works
Optimal Dose of Neuroleptic in Acute Schizophrenia
McEvoy, J. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320063009 · Cited by 384 · see citing works
Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors
Pazos, A., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90327-7 · Cited by 355 · see citing works
Nordström, A., Farde, L., Nyberg, S., Karlsson, P., Halldin, C., & Sedvall, G. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1444 · Cited by 339 · see citing works
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · PubMed · Cited by 322 · see citing works
Tollefson, G. D., & Sanger, T. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 306 · see citing works
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study
Kapur, S., Remington, G. J., Jones, C. E., Wilson, A., DaSilva, J. N., Houle, S., & Zipursky, R. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.7.948 · Cited by 251 · see citing works
Self-citationKapur, S., Remington, G. J., Zipursky, R. B., Wilson, A. A., & Houle, S. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02037-j · Cited by 229 · see citing works
Self-citationFarde, L., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C., & ERICSSON, B. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00004 · Cited by 157 · see citing works
A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects
Nyberg, S. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00218-7 · Cited by 133 · see citing works
Kapur, S., Zipursky, R. B., Roy, P., Jones, C., Remington, G. J., Reed, K. L., & Houle, S. (1997) · Psychopharmacology · doi:10.1007/s002130050277 · Cited by 126 · see citing works
Self-citationPilowsky, L. S., Busatto, G. F., Taylor, M., Sharma, T., Sigmundsson, T., Costa, D. C., Ell, P. J., & Nohria, V. (1996) · Psychopharmacology · doi:10.1007/bf02245615 · Cited by 120 · see citing works
Blin, J., Sette, G., Fiorelli, M., Blétry, O., Elghozi, J. L., Crouzel, C., & Baron, J. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01229.x · Cited by 106 · see citing works
Blin, J., Pappatà, S., Kiyosawa, M., Crouzel, C., & Baron, J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90635-8 · Cited by 94 · see citing works
A new framework for investigating antipsychotic action in humans: lessons from PET imaging
Kapur, S. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000327 · Cited by 79 · see citing works
Self-citationThe Role of Serotonin in Schizophrenia and the Place of Serotonin-Dopamine Antagonist Antipsychotics
MELTZER, H. Y. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00001 · Cited by 76 · see citing works
High-Dose Olanzapine for Treatment-Refractory Schizophrenia
Sheitman, B., Lindgren, J. C., Early, J. J., & Sved, M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1626 · Cited by 57 · see citing works
Further evidence of a dose-response threshold for haloperidol in psychosis
Stone, C. K., Garve, D. L., Griffith, J., Hirschowitz, J., & Bennett, J. E. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1210 · Cited by 54 · see citing works
Nyberg, S., Halldin, C., & Dahl, M. (1995) · Psychopharmacology · doi:10.1007/bf02246302 · Cited by 41 · see citing works
The D2 Receptor Occupancy Profile of Loxapine Determined Using PET
Kapur, S. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00100-5 · Cited by 37 · see citing works
Self-citationSmith, R. C., Chua, J. W., Lipetsker, B., & Bhattacharyya, A. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1004 · Cited by 37 · see citing works
Petit-Taboué, M.-C., Landeau, B., Osmont, A., Tillet, I., Barré, L., & Baron, J. (1996) · PubMed · Cited by 36 · see citing works
Loc’h, C., Halldin, C., Bottlaender, M., Swahn, C.-G., Moresco, R.-M., Mazière, M., Farde, L., & Maziere, B. (1996) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(96)00078-9 · Cited by 31 · see citing works
Kapur, S., JONES, C., DaSilva, J. N., Wilson, A. A., & Houle, S. (1997) · Nuclear Medicine Communications · doi:10.1097/00006231-199705000-00002 · Cited by 30 · see citing works
Self-citationA pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine
Cavallaro, R., Colombo, C., & Smeraldi, E. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100310 · Cited by 25 · see citing works
Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics?
LACEY, R. L., Preskorn, S., & Jerkovich, G. S. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1401a · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140 · see citing works
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899 · see citing works
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 778 · see citing works
Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711 · see citing works
Self-citationHalf a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638 · see citing works
Self-citationAntipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 596 · see citing works
Dorph‐Petersen, K., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300710 · Cited by 438 · see citing works
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396 · see citing works
Self-citationKapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390 · see citing works
Self-citationKaar, S., Natesan, S., McCutcheon, R., & Howes, O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 348 · see citing works
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372 · see citing works
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V. S., Hussey, D. F., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 339 · see citing works
Self-citationMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · see citing works
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324 · see citing works
Self-citationSchizophrenia: from phenomenology to neurobiology
Wong, A. H. C., & Tol, H. H. M. V. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00035-6 · Cited by 282 · see citing works
Imaging the serotonin transporter during major depressive disorder and antidepressant treatment
Meyer, J. H. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0709 · Cited by 273 · see citing works
Freudenreich, O., & GOFF, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 260 · see citing works
Probing the human hippocampus using rCBF: Contrasts in schizophrenia
Medoff, D. R., Holcomb, H. H., Lahti, A. C., & Tamminga, C. A. (2001) · Hippocampus · doi:10.1002/hipo.1070 · Cited by 257 · see citing works
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250 · see citing works
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
Meltzer, H. Y., & HUANG, M. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248 · see citing works
Clinical Pharmacokinetics of Atypical Antipsychotics
Mauri, M. C., Volonteri, L. S., Colasanti, A., Fiorentini, A., Gaspari, I. F. D., & Bareggi, S. R. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746050-00001 · Cited by 247 · see citing works
Vanover, K. E., Davis, R. E., Zhou, Y., Ye, W., Brašić, J. R., Gapasin, L., Saillard, J., Weingart, M., Litman, R. E., Mates, S. L., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0251-1 · Cited by 242 · see citing works
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237 · see citing works
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
CASALE, A. D., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 231 · see citing works
Bhana, N., Foster, R. H., Olney, R., & Plosker, G. L. (2001) · Drugs · doi:10.2165/00003495-200161010-00011 · Cited by 217 · see citing works
Pharmacokinetics and tissue distribution of olanzapine in rats
Aravagiri, M., Teper, Y., & Marder, S. R. (1999) · Biopharmaceutics & Drug Disposition · doi:10.1002/1099-081x(199911)20:8 · Cited by 202 · see citing works
Mechanism of New Antipsychotic Medications
Gründer, G., Carlsson, A., & Wong, D. F. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.10.974 · Cited by 199 · see citing works
What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?
Knegtering, H., van der Moolen, A. E. G. M., Castelein, S., Kluiter, H., & van den Bosch, R. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00130-0 · Cited by 196 · see citing works
Konopaske, G. T., Dorph‐Petersen, K., Pierri, J. N., Wu, Q., Sampson, A. R., & Lewis, D. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301233 · Cited by 192 · see citing works
Mamo, D. C., Kapur, S., Shammi, C., Papatheodorou, G. N., Mann, S. W., Therrien, F., & Remington, G. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.818 · Cited by 189 · see citing works
Self-citationAntipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185 · see citing works
Pharmacological causes of hyperprolactinemia.
Torre, D. L., & Falorni, A. (2007) · PubMed Central · Cited by 183 · see citing works
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179 · see citing works
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia
Nord, M., & Farde, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00222.x · Cited by 178 · see citing works
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Mauri, M. C., Paletta, S., Pace, C. D., Reggiori, A., Cirnigliaro, G., Valli, I., & Altamura, A. C. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0664-3 · Cited by 178 · see citing works
Vernon, A. C., Natesan, S., Modo, M., & Kapur, S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.010 · Cited by 173 · see citing works
Self-citationHodé, Y., Reimold, M., Demazières, A., Reischl, G., Bayle, F., Nuss, P., Hameg, A., Dib, M., & Macher, J. P. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2172-z · Cited by 171 · see citing works
Tauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., Remington, G., Zipursky, R. B., & Kapur, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1620 · Cited by 159 · see citing works
Self-citationA Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Diverse Roles of Neurotensin Agonists in the Central Nervous System
Boules, M., Li, Z., Smith, K., Fredrickson, P. A., & Richelson, E. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00036 · Cited by 149 · see citing works
Dopamine D2 Receptor Occupancy and Clinical Effects
Uchida, H., Takeuchi, H., Graff‐Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182214aad · Cited by 148 · see citing works
Yatham, L. N., Liddle, P. F., Dennie, J., Shiah, I., Adam, M. J., Lane, C. J., Lam, R. W. M., & Ruth, T. J. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.705 · Cited by 147 · see citing works
A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning
Knegtering, R., Castelein, S., Bous, H., van der Linde, J., Bruggeman, R., Kluiter, H., & van den Bosch, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106220.36344.04 · Cited by 147 · see citing works
D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
Gefvert, O., Lundberg, T., Wieselgren, I., Bergström, M., Långström, B., Wiesel, F., & Lindström, L. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00133-4 · Cited by 145 · see citing works
Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents
Marx, C., Vandoren, M. J., Duncan, G., Lieberman, J., & Morrow, A. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300015 · Cited by 146 · see citing works
Role of dopamine D(2) receptors for antipsychotic activity.
Ginovart, N., & Kapur, S. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25761-2_2 · Cited by 145 · see citing works
Self-citationHyperprolactinemia associated with psychotropics—a review
Madhusoodanan, S., Parida, S., & Jiménez, C. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1116 · Cited by 137 · see citing works
Agid, O., Mamo, D. C., Ginovart, N., Vitcu, I., Wilson, A. A., Zipursky, R. B., & Kapur, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301242 · Cited by 136 · see citing works
Self-citationTarget site occupancy: emerging generalizations from clinical and preclinical studies.
Grimwood, S., & Hartig, P. (2009) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2009.03.002 · Cited by 124 · see citing works
Functional effects of antipsychotic drugs: comparing clozapine with haloperidol
Lahti, A. C., Holcomb, H. H., Weiler, M. A., Medoff, D. R., & Tamminga, C. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01602-5 · Cited by 134 · see citing works
Current and Novel Approaches to the Drug Treatment of Schizophrenia
Rowley, M., Bristow, L. J., & Hutson, P. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0002432 · Cited by 129 · see citing works
Challenges in the management of bipolar depression.
Suppes, T. M., Kelly, D. I., & Perla, J. M. (2005) · PubMed · Cited by 128 · see citing works
Atypicality of Atypical Antipsychotics
Farah, A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0602 · Cited by 128 · see citing works
Skapinakis, P., Papatheodorou, T., & Mavreas, V. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.002 · Cited by 128 · see citing works
Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia
Angelucci, F., Mathé, A. A., & Aloe, L. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46011-1 · Cited by 127 · see citing works
Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis
Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182983ffa · Cited by 125 · see citing works
Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine
Kessler, R. M., Ansari, M., Riccardi, P., Li, R., Jayathilake, K., Dawant, B., & Meltzer, H. Y. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301108 · Cited by 123 · see citing works
Talbot, P. S. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00099-8 · Cited by 119 · see citing works
Therapeutic Monitoring of New Antipsychotic Drugs
Hiemke, C., Dragičević, A., Gründer, G., Hätter, S., Sachse, J., Vernaleken, I., & Müller, M. J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00012 · Cited by 111 · see citing works
Alterations of Serotonin Transmission in Schizophrenia
Abi‐Dargham, A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78005-9 · Cited by 98 · see citing works
Kasper, S. F., Tauscher, J. T., Kufferle, B., Barnas, C., Pezawas, L., & Quiner, S. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014189 · Cited by 98 · see citing works
Upcoming Agents for the Treatment of Schizophrenia
Bishara, D., & Taylor, D. M. (2008) · Drugs · doi:10.2165/0003495-200868160-00002 · Cited by 94 · see citing works
Fonseka, T. M., Richter, M. A., & Müller, D. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0510-8 · Cited by 93 · see citing works
Maina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 92 · see citing works
Kasper, S. F., Tauscher, J. T., Willeit, M., Stamenkovic, M., Neumeister, A., Kufferle, B., Barnas, C., Stastny, J., Praschak-Rieder, N., Pezawas, L., et al. (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150614 · Cited by 90 · see citing works
Neuroimaging in psychiatry: An update.
Abou-Saleh, M. (2006) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.06.012 · Cited by 44 · see citing works
Duncan, G. E., Miyamoto, S., Leipzig, J. N., & Lieberman, J. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39197-9 · Cited by 90 · see citing works
Duncan, G. E., Zorn, S. J., & Lieberman, J. A. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000581 · Cited by 90 · see citing works
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
Remington, G. J. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0334 · Cited by 89 · see citing works
Self-citationThe new generation of antipsychotic drugs: how atypical are they?
Goldstein, J. M. (2000) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145700002042 · Cited by 85 · see citing works
Juckel, G., Gallinat, J., Riedel, M. J., Sokullu, S., Schulz, C. O., Möller, H., Müller, N., & Hegerl, U. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00016-1 · Cited by 84 · see citing works
Turrone, P., Remington, G. J., & Nóbrega, J. N. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00008-8 · Cited by 84 · see citing works
Self-citationAngelucci, F., Aloe, L., Iannitelli, A., Gruber, S. H. M., & Mathé, A. A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.11.005 · Cited by 84 · see citing works
Tauscher, J. T., Kufferle, B., Asenbaum, S., Fischer, P. Q., Pezawas, L., Barnas, C., Tauscher‐Wisniewski, S., Brücke, T., & Kasper, S. F. (1999) · Psychopharmacology · doi:10.1007/s002130050822 · Cited by 84 · see citing works
In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia
Raedler, T. J. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00162-1 · Cited by 82 · see citing works
Occupancy of Striatal and Extrastriatal Dopamine D2/D3 Receptors by Olanzapine and Haloperidol
KESSLER, R. M., Ansari, M. S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B. M., & Meltzer, H. Y. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300836 · Cited by 80 · see citing works
Amato, D., Vernon, A. C., & Papaleo, F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 80 · see citing works
Choosing the Right Dose of Antipsychotics in Schizophrenia
Tauscher, J. T., & Kapur, S. (2001) · CNS Drugs · doi:10.2165/00023210-200115090-00001 · Cited by 80 · see citing works
Self-citationDo antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms?
Sareen, J., Kirshner, A., Lander, M., Kjernisted, K. D., Eleff, M. K., & Reiss, J. P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.03.011 · Cited by 79 · see citing works
Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy
Pani, L., Pira, L., & Marchese, G. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.02.005 · Cited by 78 · see citing works
Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders
Verhoeff, N. (1999) · Psychopharmacology · doi:10.1007/s002130051163 · Cited by 79 · see citing works
Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain
HUANG, X., HAN, M., HUANG, X., Zavitsanou, K., & Deng, C. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.03.040 · Cited by 76 · see citing works
Antipsychotic drugs, dopamine receptors, and schizophrenia
Seeman, P. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00007-4 · Cited by 73 · see citing works
The Effects of Antipsychotics on Prolactin Levels and Women’s Menstruation
Bargiota, S. I., Bonotis, K. S., Messinis, I. E., & Angelopoulos, N. V. (2013) · Schizophrenia Research and Treatment · doi:10.1155/2013/502697 · Cited by 75 · see citing works
Knegtering, H., Boks, M., Blijd, C., Castelein, S., van den Bosch, R. J., & Wiersma, D. (2006) · Journal of Sex & Marital Therapy · doi:10.1080/00926230600666378 · Cited by 74 · see citing works
Purdon, S. E., Woodward, N. D., Lindborg, S. R., & Stip, É. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1505-z · Cited by 73 · see citing works
Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia
Nieman, D. H., Bour, L. J., Linszen, D. H., Goede, J., Koelman, J. H. T. M., Gersons, B. P. R., & de Visser, B. W. O. (2000) · Neurology · doi:10.1212/wnl.54.4.866 · Cited by 71 · see citing works
Kalinichev, M., Rourke, C., Daniels, A. J., Grizzle, M. K., Britt, C. S., Ignar, D. M., & Jones, D. N. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0081-9 · Cited by 70 · see citing works
Uchida, H., Kapur, S., Mulsant, B. H., Graff‐Guerrero, A., Pollock, B. G., & Mamo, D. C. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318198776d · Cited by 70 · see citing works
Self-citationVoineskos, A. N., Wilson, A. A., Boovariwala, A., Sagrati, S., Houle, S., Rusjan, P., Sokolov, S. T. H., Spencer, E. P., Ginovart, N., & Meyer, J. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0806-z · Cited by 69 · see citing works
Self-citationThe Effects of Atypical Antipsychotics on Serum Prolactin Levels
Hamner, M. B. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1021138603935 · Cited by 69 · see citing works
Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial
Metin, Ö., Yazıcı, K., Tot, Ş., & Yazıcı, A. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.512 · Cited by 68 · see citing works
Mamo, D. C., Kapur, S., Keshavan, M. S., Laruelle, M. A., Taylor, C. C., Kothare, P. A., Barsoum, P., & McDonnell, D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301409 · Cited by 67 · see citing works
Self-citationPharmacogenetics of antipsychotic-induced side effects
Lencz, T., & Malhotra, A. K. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/tlencz · Cited by 66 · see citing works
Kapur, S., Cho, R., Jones, C., McKay, G., & Zipursky, R. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00204-2 · Cited by 65 · see citing works
Self-citationLahti, A. C., Weiler, M. A., Medoff, D. R., Tamminga, C. A., & Holcomb, H. H. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2005.02.006 · Cited by 65 · see citing works
Selvı, Y., Atlı, A., Aydın, A., Beşiroğlu, L., Özdemir, P. G., & Özdemir, O. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1169 · Cited by 64 · see citing works
Bishara, D., Olofinjana, O., Sparshatt, A., Kapur, S., Taylor, D. M., & Patel, M. X. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828b28d5 · Cited by 64 · see citing works
Self-citationRosengarten, H., & Quartermain, D. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00221-x · Cited by 63 · see citing works
- Authors
- Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S.
- Venue
- American Journal of Psychiatry
- Published
- 1998-07-01
- Volume
- 155
- Issue
- 7
- Pages
- 921-928
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2163010981
- Cited by
- 370
- References
- 41
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 10 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 7 · 2014: 9 · 2013: 19 · 2012: 14
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- olanzapine, schizophrenia, dopamine D2 receptor occupancy, atypical antipsychotics, dose dependence, extrapyramidal symptoms, prolactin elevation, [11C]raclopride, clozapine, risperidone
- MeSH terms
- Olanzapine, Adult, Benzodiazepines, Carbon Radioisotopes, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorine Radioisotopes, Humans, Male, Pirenzepine, Prolactin, Pyrimidinones, Receptors, Serotonin, Salicylamides, Schizophrenia, Tomography, Emission-Computed, Antipsychotic Agents, Treatment Outcome, Receptors, Dopamine D2, Raclopride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
